John Muir Health

Allergy and diseases caused or complicated by allergy, such as asthma, or diseases with symptoms which mimic allergy, are among the most widespread and costly health problems in the world.

John Muir Health, MuirLab will soon provide testing for allergy that is safe, simple, and accurate with groundbreaking technology with the latest generation of automated allergy diagnostic systems.

Detection of immunoglobulin E (IgE) antibodies and determination of specific allergens allow for better outcomes and increased quality of life for allergy patients. To be reliable, the testing system used to detect allergy must be standardized. Phadia allergy test systems, along with all their components, are standardized against World Health Organization reference preparations for reproducible, reliable results. Phadia, a global leader in allergy diagnostics research and development since 1974, offers advanced automated instrumentation to process the ImmunoCAP® technology-based test kits for allergy, and inflammation markers for asthma and anaphylaxis. The ImmunoCAP® instrument provides innovative software and hardware solutions that meet laboratory automation and throughput requirements.

ImmunoCAP® Specific IgE assays are the first to be FDA cleared for the quantitative measurement of specific IgE. The most significant features of ImmunoCAP technology are extensive quality control measures, excellent allergen and reagent source materials, and calibration to WHO reference preparations. In addition, the structural design of ImmunoCAP® allows for automation and thorough elimination of unbound nonspecific material in the reaction complex, resulting in highly reproducible, accurate, and quantitative results.